Trial Profile
A phase 2, randomized placebo controlled study of Ustekinumab in patients with Active Systemic Lupus Erythematosus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Feb 2020
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary) ; Ustekinumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- 24 Nov 2018 New trial record
- 24 Oct 2018 Results assessing efficacy of ustekinumab in patients with active systemic lupus erythematosus, presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.